Evidence map›Paper›PMID 36379917›Full record

ReviewBlood cancer journal2022

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020.

Oliver Van Oekelen, Nicole Birrer, William Wesson, Vincent L Galate, Edward R Scheffer Cliff, Aaron M Goodman, Al-Ola Abdallah, Rajshekhar Chakraborty, Vinay Prasad, Ghulam Rehman Mohyuddin

Abstract readReviewLetter
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Oliver Van OekelenDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, Department of Internal Medicine, New York, NY, USA.ORCID 0000-0002-5824-197X
Nicole BirrerUniversity of Utah, Huntsman Cancer Center, Division of Hematology, Salt Lake City, Utah, USA.
William WessonUniversity of Kansas, University of Kansas School of Medicine, Kansas City, Kansas, USA.ORCID 0000-0002-9534-0512
Vincent L GalateUniversity of Kansas, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Edward R Scheffer CliffProgram on Regulation, Therapeutics and Law, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5977-907X
Aaron M GoodmanDivision of Blood and Marrow Transplantation, University of California San Diego, San Diego, CA, USA.
Al-Ola AbdallahUniversity of Kansas, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Rajshekhar ChakrabortyDepartment of Hematology, Columbia University, New York, NY, USA.
Vinay PrasadDivision of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Ghulam Rehman MohyuddinUniversity of Utah, Huntsman Cancer Center, Division of Hematology, Salt Lake City, Utah, USA. g.mohyuddin@hci.utah.edu.ORCID 0000-0001-6464-783X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaClinical Trials as TopicHumansNeoplasm, Residual

Identifiers

PMID36379917
PMCPMC9666639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.